Congratulations to our faculty @Neerajaiims for leading this @theNCI funded @SWOG S1216 study published in @CCR_AACR today + to @KohliMask1020 ,coauthor. Presence of CTCs is a bad sign and these men with new metastatic #prostatecancer need novel trials at
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
RT @neerajaiims: Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prosta…
Our study in @CCR_AACR today: 1st report from a federally funded prospective trial (@SWOG S1216) in new metastatic #prostatecancer (mCSPC)👉showing tremendous negative impact of baseline CTCs on survival outcomes👇These men need novel trials https://t.co/jgl
Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216) https://t.co/N1GnqtTt1f